Security Snapshot

THERAPEUTICSMD INC - COM (TXMD) Institutional Ownership

CUSIP: 88338N107

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2022

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / COM
Symbol
TXMD on Nasdaq
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • TXMD - THERAPEUTICSMD INC - COM is tracked under CUSIP 88338N107.
  • Latest finished 13F holder period is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 2 to 0 between Q2 2022 and Q3 2022.
  • SEC-reported value moved from $138,000 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

88338N107

Latest holder period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

TXMD full holder history TherapeuticsMD, Inc. SEC filings TherapeuticsMD, Inc. company facts TherapeuticsMD, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
35
Latest
n/a
Rows shown
1-25 of 35
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2022 Q3 0 $0 -$138,000 0
2022 Q2 13,882 $138,000 -$40,657,805 $10.06 2
2022 Q1 106,249,720 $40,383,995 -$6,460,833 $0.38 107
2021 Q4 123,989,841 $44,113,283 -$5,136,500 $0.36 118
2021 Q3 132,623,961 $98,181,827 -$35,237,991 $0.74 143
2021 Q2 168,594,448 $200,534,644 -$7,293,146 $1.19 148
2021 Q1 174,027,984 $233,195,315 +$19,299,909 $1.34 154
2020 Q4 161,086,122 $195,000,979 +$2,870,955 $1.21 150
2020 Q3 157,569,577 $249,322,171 +$8,915,683 $1.58 139
2020 Q2 152,335,132 $190,408,846 -$36,023,732 $1.25 142
2020 Q1 182,844,612 $189,844,871 -$31,618,067 $1.06 135
2019 Q4 192,502,060 $466,882,212 +$46,177,594 $2.42 162
2019 Q3 172,591,588 $626,565,901 -$57,124,136 $3.63 145
2019 Q2 188,901,090 $489,428,303 -$20,791,317 $2.60 144
2019 Q1 191,057,703 $930,418,803 +$25,180,934 $4.87 139
2018 Q4 186,489,933 $710,578,290 +$23,585,017 $3.81 133
2018 Q3 178,040,270 $1,167,923,446 +$136,966,572 $6.56 151
2018 Q2 157,165,492 $980,713,228 -$29,803,080 $6.24 141
2018 Q1 162,504,460 $791,412,125 -$4,590,259 $4.87 139
2017 Q4 162,564,564 $981,884,925 -$9,661,276 $6.04 140
2017 Q3 164,535,449 $866,656,619 +$45,414,189 $5.29 132
2017 Q2 155,831,246 $821,246,855 -$59,727,020 $5.27 116
2017 Q1 164,032,510 $1,180,505,857 +$86,656,418 $7.20 133
2016 Q4 164,362,294 $948,393,873 +$51,055,130 $5.77 144
2016 Q3 155,172,033 $1,056,251,015 -$38,331,278 $6.81 134
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .